A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
NCT06075810
This study is recruiting at 3 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Breast Cancer
- Breast Neoplasm
- Breast Cancer Stage IV
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 21 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- MBQ Pharma
- Last updated on ClinicalTrials.gov
- August 31, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Precision Next Gen Oncology & Research Center · Beverly Hills, CA
Florida · 1
- Florida Cancer Specialists / Sarah Cannon Research Institute / SCRI · Sarasota, FL
Tennessee · 1
- Sarah Cannon Research Institute/SCRI · Nashville, TN
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.